GlassScriptPhysician profile
Kisha J Morgan
NPI 1427080910
$4,850.64
in general payments reported to CMS, 2019-2025
30 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $277 · 2021: $431 · 2022: $309 · 2023: $542 · 2024: $634 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.19 |
| Education | $223.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $872.30 | 2019 | |
| Glaxosmithkline, LLC. | $717.03 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $607.07 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $573.72 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.47 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $257.54 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Merck Sharp & Dohme LLC | $199.78 | 2022-2025 | Winrevair, Zerbaxa, Recarbrio |
| Grifols USA, LLC | $123.62 | 2021-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $120.87 | 2019-2025 | Orenitram, Remodulin, Tyvaso |
| Amgen INC. | $110.93 | 2023-2025 | Tezspire, Tavneos |
| Janssen Pharmaceuticals, INC | $98.77 | 2020-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $77.32 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $71.40 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.59 | 2021-2025 | Glassia |
| Shionogi INC | $62.23 | 2022-2024 | Fetroja |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $58.70 | 2019-2022 | |
| Gilead Sciences, INC. | $51.80 | 2019-2023 | |
| Electromed, INC. | $50.45 | 2024-2025 | Smartvest |
| Pulmonx Corporation | $50.00 | 2019 | |
| Verona Pharma, INC. | $47.30 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $42.58 | 2020-2023 | Wakix |
| Genzyme Corporation | $35.72 | 2025 | |
| Nabriva Therapeutics, Plc | $24.51 | 2021-2022 | |
| Vapotherm INC | $21.90 | 2022 | |
| Mylan Specialty L.P. | $18.24 | 2023 | Yupelri |
| Genentech USA, INC. | $18.21 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.06 | 2021 | |
| Tactile Systems Technology INC | $15.53 | 2024 | Entre Plus, Flexitouch Plus |
| Sunovion Pharmaceuticals INC. | $14.07 | 2019 | |
| Pfizer INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kisha Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.